C Spyropoulos, MD, FACP, FCCP, FRCPC

About the researcher:


Internal medicine

Dr. Spyropoulos was Founder and former Medical Director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is currently an Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and System Director of Anticoagulation Services and Clinical Thrombosis for the North Shore Long Island Jewish Health System. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and Fellow of the Royal College of Physicians, Canada.

Dr. Spyropoulos has helped to develop protocols using low molecular weight heparin in outpatient-based treatment of venous thromboembolic disease, patient self-testing of warfarin, perioperative “bridging” for patients on chronic anticoagulation, medical inpatient prophylaxis, protocols with regards to the use of anticoagulants for HIT, and clinical use of new anticoagulants and in special patient populations. Dr. Spyropoulos is active in assessing outcome analyses of these protocols and has lectured extensively both nationally and internationally on these issues, in addition to developing the clinical thrombosis curriculum at the University of New Mexico Health Sciences Center.

Research focus:

Research interests

Anticoagulation, especially with the novel oral anticoagulants
Clinical thrombosis, especially with high-risk patients populations (cancer, antiphospholipid syndrome) or in high-risk situations (periprocedural antithrombotic therapy)

Research training opportunities for residents and fellows:

  • Conducting large retrospective analysis using existing anticoagulant data software systems
  • Publishing relevant case series of special patient populations on anticoagulant therapy of interest
  • Conducting and publishing sub studies within existing large global clinical studies
  • Creating and managing a prospective international registry of periprocedural novel oral anticoagulant use as part of the SCC of the International Society of Thrombosis and Haemostasis, under an SSC working group grant


University of Pennsylvania School of Medicine

Degree: MD

University of New Mexico School of Medicine

Degree: Medical Internship

University of New Mexico School of Medicine

Degree: Residency

Honors and awards


National Heart Lung Blood Institute, BRIDGE, Federal


Jansen, MARINER, Industry


Boehringer Ingelheim, MARINER, Industry


Canadian Institute for Healthcare Research, PAUSE, Federal


  1. Predicting the Risk of Venous Thromboembolism in Patients Hospitalized with Heart Failure. Mebazaa A, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Merli G, Schellong S, Spyropoulos AC, Tapson VF, De Sanctis Y, Cohen AT. Circulation. 2014 Jun 26. pii: CIRCULATIONAHA.113.003126. [Epub ahead of print] PMID: 24970782
  2. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC; ROCKET AF Investigators. Circulation. 2014 May 6;129(18):1850-9. doi:10.1161/CIRCULATIONAHA.113.005754. Epub 2014 Feb 19.PMID: 24552831
  3. Venous Thromboembolism Risk in Patients With Inflammatory Bowel Disease: Defining the Benefits of Pharmacologic Prophylaxis. Sultan K, Brun A, Spyropoulos AC. Clin Gastroenterol Hepatol. 2014 Apr 1. pii: S1542-3565(14)00475-3. doi: 10.1016/j.cgh.2014.03.025. [Epub ahead of print] No abstract available. PMID: 24703865
  4. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma. Papageorgiou C, Vandreden P, Marret E, Bonnet F, Robert F, Spyropoulos A, Galea V, Elalamy I, Hatmi M, Gerotziafas GT.Thromb Res. 2013 Nov;132(5):584-91. doi: 10.1016/j.thromres.2013.07.005. Epub 2013 Aug 29. PMID: 24094602.
  5. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Mahan CE, Fisher MD, Mills RM, Fields LE, Stephenson JJ, Fu AC, Spyropoulos AC. Thromb Res. 2013 Nov;132(5):520-6. doi: 10.1016/j.thromres.2013.08.013. Epub 2013 Aug 28. PMID: 24080150